| Roles of IL-1 in cancer: from tumor progression to resistance to targeted therapies V Gelfo, D Romaniello, M Mazzeschi, M Sgarzi, G Grilli, A Morselli, ... International journal of molecular sciences 21 (17), 6009, 2020 | 116 | 2020 |
| An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors M Mancini, H Gal, N Gaborit, L Mazzeo, D Romaniello, TM Salame, ... EMBO Molecular Medicine 10 (2), 294-308, 2018 | 47 | 2018 |
| A combination of approved antibodies overcomes resistance of lung cancer to osimertinib by blocking bypass pathways D Romaniello, L Mazzeo, M Mancini, I Marrocco, A Noronha, M Kreitman, ... Clinical Cancer Research 24 (22), 5610-5621, 2018 | 43 | 2018 |
| Acetylation and phosphorylation of STAT3 are involved in the responsiveness of microglia to beta amyloid M Eufemi, R Cocchiola, D Romaniello, V Correani, L Di Francesco, ... Neurochemistry International 81, 48-56, 2015 | 40 | 2015 |
| STAT3 post-translational modifications drive cellular signaling pathways in prostate cancer cells R Cocchiola, E Rubini, F Altieri, S Chichiarelli, G Paglia, D Romaniello, ... International journal of molecular sciences 20 (8), 1815, 2019 | 36 | 2019 |
| Cancer immunotherapy: the dawn of antibody cocktails I Marrocco, D Romaniello, Y Yarden Human Monoclonal Antibodies: Methods and Protocols, 11-51, 2019 | 35 | 2019 |
| Targeting HER3, a catalytically defective receptor tyrosine kinase, prevents resistance of lung cancer to a third-generation EGFR kinase inhibitor D Romaniello, I Marrocco, N Belugali Nataraj, I Ferrer, D Drago-Garcia, ... Cancers 12 (9), 2394, 2020 | 34 | 2020 |
| Comparative analysis of the interaction between different flavonoids and PDIA3 F Giamogante, I Marrocco, D Romaniello, M Eufemi, S Chichiarelli, ... Oxidative medicine and cellular longevity 2016, 2016 | 25 | 2016 |
| ETS proteins bind with glucocorticoid receptors: Relevance for treatment of Ewing sarcoma S Srivastava, NB Nataraj, A Sekar, S Ghosh, C Bornstein, D Drago-Garcia, ... Cell Reports 29 (1), 104-117. e4, 2019 | 18 | 2019 |
| Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models I Marrocco, D Romaniello, I Vaknin, D Drago‐Garcia, R Oren, ML Uribe, ... EMBO Molecular Medicine 13 (4), e13144, 2021 | 13 | 2021 |
| Analysis of STAT3 post-translational modifications (PTMs) in human prostate cancer with different Gleason Score R Cocchiola, D Romaniello, C Grillo, F Altieri, M Liberti, FM Magliocca, ... Oncotarget 8 (26), 42560, 2017 | 12 | 2017 |
| Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies R Maron, B Schechter, NB Nataraj, S Ghosh, D Romaniello, I Marrocco, ... Biochemical and biophysical research communications 513 (1), 219-225, 2019 | 9 | 2019 |
| The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer M Mazzeschi, M Sgarzi, D Romaniello, V Gelfo, C Cavallo, F Ambrosi, ... Journal of Experimental & Clinical Cancer Research 41 (1), 113, 2022 | 8 | 2022 |
| Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization D Romaniello, V Gelfo, F Pagano, E Ferlizza, M Sgarzi, M Mazzeschi, ... Cellular & Molecular Biology Letters 27 (1), 20, 2022 | 7 | 2022 |
| Neuregulin 4 boosts the efficacy of anti-ERBB2 neutralizing antibodies C Miano, D Romaniello, M Mazzeschi, A Morselli, S Da Pra, F Sacchi, ... Frontiers in Oncology 12, 831105, 2022 | 5 | 2022 |
| NRG1/ERBB3/ERBB2 axis triggers anchorage-independent growth of basal-like/triple-negative breast cancer cells C Miano, A Morselli, F Pontis, C Bongiovanni, F Sacchi, S Da Pra, ... Cancers 14 (7), 1603, 2022 | 5 | 2022 |
| β-Hexachlorocyclohexane drives carcinogenesis in the human normal bronchial epithelium cell line BEAS-2B E Rubini, M Minacori, G Paglia, F Altieri, S Chichiarelli, D Romaniello, ... International Journal of Molecular Sciences 22 (11), 5834, 2021 | 4 | 2021 |
| L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab I Marrocco, S Giri, A Simoni-Nieves, N Gupta, A Rudnitsky, Y Haga, ... Cell Reports Medicine 4 (8), 2023 | 3 | 2023 |
| Targeting HER3, a Catalytically Defective Receptor Tyros‑ine Kinase, Prevents Resistance of Lung Cancer to a Third‑Generation EGFR Kinase Inhibitor. Cancers (Basel). 2020; 12 (9) D Romaniello, I Marrocco, N Belugali Nataraj, I Ferrer, D Drago-Garcia, ... | 3 | |
| IL-1 and senescence: friends and foe of EGFR neutralization and immunotherapy D Romaniello, V Gelfo, F Pagano, M Sgarzi, A Morselli, C Girone, ... Frontiers in Cell and Developmental Biology 10, 1083743, 2023 | 2 | 2023 |
Ilaria MarroccoSenior Posdoc, Weizmann Institute of scienceVerified email at weizmann.ac.il
